Neuroone Medical Technologies (NMTC) Long-Term Deferred Tax (2018 - 2025)

Neuroone Medical Technologies has disclosed Long-Term Deferred Tax across 8 years of filings, most recently posting $20.6 million for Q3 2025.

• Quarterly Long-Term Deferred Tax rose 7.32% year-over-year to $20.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $20.6 million (up 7.32% YoY) and the FY2025 annual result came in at $20.6 million, up 7.32% from the prior year.
• Long-Term Deferred Tax climbed to $20.6 million in Q3 2025, from $19.2 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $20.6 million in Q3 2025 and bottomed at $8.9 million in Q3 2021.
• The 5-year median for Long-Term Deferred Tax is $15.6 million (2023), against an average of $15.3 million.
• Year-over-year, Long-Term Deferred Tax soared 55.81% in 2021 and grew 7.32% in 2025.
• Neuroone Medical Technologies' Long-Term Deferred Tax stood at $8.9 million in 2021, then jumped by 35.9% to $12.1 million in 2022, then increased by 29.65% to $15.6 million in 2023, then gained by 22.59% to $19.2 million in 2024, then climbed by 7.32% to $20.6 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $20.6 million, $19.2 million, and $15.6 million for Q3 2025, Q3 2024, and Q3 2023 respectively.